However, in the last decade, the treatment options for melanoma have significantly advanced due to the emergence of immunotherapies and targeted therapies, including anti-CTLA4 and anti-PD-1 checkpoint inhibitors, as well as BRAF and mitogen-activated extracellular signal-regulated kinase (MEK) inhibitors[3]. This evidence concerns the gene BRAF and melanoma.